Revvity

Revvity (formerly the core life sciences and clinical diagnostics division of PerkinElmer) is a massive global powerhouse in biotechnology and healthcare innovation, fundamentally expanding the boundaries of human potential through science. Officially rebranded in 2023 and headquartered in Waltham, Massachusetts, the company operates at the absolute cutting edge of disease research and drug discovery. Under the hood, Revvity provides an end-to-end ecosystem of highly advanced reagents, automated liquid handling instruments, and sophisticated informatics (such as the Signals™ software suite). Their portfolio encompasses everything from the Pin-point™ base editing platform and CRISPR workflows to high-throughput cellular imaging and newborn genomic screening. Their primary target audience spans top-tier academic researchers, 94% of the top 50 global pharmaceutical companies, and massive clinical laboratories that desperately need to accelerate translational multi-omics and biomarker identification. What sets Revvity apart in the highly complex bio-tech industry is its staggering real-world impact—employing around 11,000 people globally and actively screening over 33 million babies annually for life-threatening disorders, effectively bridging the gap from early discovery directly to clinical cure.